ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

Description

Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

Conditions

Psoriasis

Talk to us

Study Overview

On this page

Study Details

Study overview

Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

Condition
Psoriasis
Intervention / Treatment

-

Contacts and Locations

East Windsor

Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States, 08520

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male or female adult ≥ 18 years of age;
  • 2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by
  • * BSA 10%
  • * PGA ≥3
  • * PASI ≥12
  • 3. Must be a candidate for phototherapy and/or systemic therapy
  • 4. Females of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.
  • 1. Non-plaque forms of psoriasis
  • 2. Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating
  • 3. Presence of significant uncontrolled medical condition that in the opinion of the investigator would affect patient safety during the trial.
  • 4. Active or untreated latent tuberculosis (TB)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Psoriasis Treatment Center of Central New Jersey,

Study Record Dates

2021-03-01